

## POUMONS

<b>Chimiothérapie 1ère ligne NSCLC Tirapazamine- Cisplatine-Vinorelbine versus Cisplatine Vinorelbine</b>	
<b>N° protocole</b>	EFC3675
<b>Promoteur</b>	SANOFI-SYNTHELABO
<b>Titre Protocole</b>	A phase III, randomized efficacy and safety study of the combination chemotherapy with Tirapazamine+Cisplatine-Vinorelbine versus Cisplatine-Vinorelbine in subjects with inoperable, previously untreated Non-Small Cell Lung Cancer
<b>Phase</b>	6 cycles de 28 jrs -) Tirapazamine 330mg/m2 en 2H -) J1 Cisplatine 100mg/m2 en 1H -) J1 Vinorelbine 25mg/m2 en 10' -) J1-8-15-22
<b>Date accord Comité d'Ethique</b>	20/11/00

<b>Chimiothérapie 1ère ligne NSCLC Stade IIIB et IV</b>	
<b>N° protocole</b>	BO16411
<b>Promoteur</b>	ROCHE
<b>Titre Protocole</b>	A phase III study of the combination chemotherapy with Cisplatine-Gemcitabine versus Cisplatine-Gemcitabine-TARCEVA in subjects with inoperable, previously untreated Non-Small Cell Lung Cancer
<b>Phase</b>	III
<b>Date accord Comité d'Ethique</b>	02/10/01

<b>Cisplatine/topotécan versus cisplatine/ VP16 dans 1ère ligne SCLC</b>	
<b>N° Protocole</b>	SKF-104864A
<b>Promoteur</b>	SmithKline Beecham
<b>Titre protocole</b>	An open-label, multicenter, randomized, phaseIII study comparing oral topotécan/cisplatine as treatment for chemotherapy-naive patients with extensive disease-small cell lung cancer.
<b>Phase</b>	III
<b>Date accord Comité d'Ethique</b>	sept-01
<b>Date fin étude</b>	